Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%
HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.86B
EPS2.7600
P/E Ratio11.63
Earnings Date08/04/2026

hrmy

Sales/Maturities of Investments

Last Annual Value

81.06M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Competitors Analysis of Sales/Maturities of Investments

HRMY · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
81.06M
-11.8%N/AN/A 
221.72M
23.0%30.3%N/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
570.00M
20.3%N/AN/A
206.65M
58.4%N/AN/A
596.29M
23.0%27.8%9.4%
405.28M
13.4%24.7%N/A
462.29M
-13.4%24.4%N/A
506.16M
39.7%N/AN/A
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

Intrinsic Value
Current Price: $32.1